A Summary of the BRIDGe Summit on Damage-Related Progression of Ulcerative Colitis: Establishing Research Priorities
Noa Krugliak Cleveland(University of Chicago), Fernando Velayos(Kaiser Permanente San Francisco Medical Center), Shane Devlin, Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Thomas Ullman(Montefiore Medical Center), David T. Rubin(University of California System), Leonard Baidoo(University of Pittsburgh Medical Center), Gil Melmed, Adam S. Cheifetz(Beth Israel Deaconess Medical Center), Brian Bressler(University of British Columbia), Laura E. Raffals, Joana Torres(University of Lisbon), Miles Sparrow(Alfred Health), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Parakkal Deepak(Washington University in St. Louis), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Florian Rieder(Cleveland Clinic)
Cited by 6
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k